2I1M

cFMS tyrosine kinase (tie2 KID) in complex with an arylamide inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.8 Å
  • R-Value Free: 0.282 
  • R-Value Work: 0.237 

wwPDB Validation 3D Report Full Report


This is version 1.4 of the entry. See complete history

Literature

Crystal structure of the tyrosine kinase domain of colony-stimulating factor-1 receptor (cFMS) in complex with two inhibitors.

Schubert, C.Schalk-Hihi, C.Struble, G.T.Ma, H.C.Petrounia, I.P.Brandt, B.Deckman, I.C.Patch, R.J.Player, M.R.Spurlino, J.C.Springer, B.A.

(2007) J.Biol.Chem. 282: 4094-4101

  • DOI: 10.1074/jbc.M608183200
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • The cFMS proto-oncogene encodes for the colony-stimulating factor-1 receptor, a receptor-tyrosine kinase responsible for the differentiation and maturation of certain macrophages. Upon binding its ligand colony-stimulating factor-1 cFMS autophosphory ...

    The cFMS proto-oncogene encodes for the colony-stimulating factor-1 receptor, a receptor-tyrosine kinase responsible for the differentiation and maturation of certain macrophages. Upon binding its ligand colony-stimulating factor-1 cFMS autophosphorylates, dimerizes, and induces phosphorylation of downstream targets. We report the novel crystal structure of unphosphorylated cFMS in complex with two members of different classes of drug-like protein kinase inhibitors. cFMS exhibits a typical bi-lobal kinase fold, and its activation loop and DFG motif are found to be in the canonical inactive conformation. Both ATP competitive inhibitors are bound in the active site and demonstrate a binding mode similar to that of STI-571 bound to cABL. The DFG motif is prevented from switching into the catalytically competent conformation through interactions with the inhibitors. Activation of cFMS is also inhibited by the juxtamembrane domain, which interacts with residues of the active site and prevents formation of the activated kinase. Together the structures of cFMS provide further insight into the autoinhibition of receptor-tyrosine kinases via their respective juxtamembrane domains; additionally the binding mode of two novel classes of kinase inhibitors will guide the design of novel molecules targeting macrophage-related diseases.


    Organizational Affiliation

    Structural Biology, Johnson & Johnson Pharmaceuticals Research and Development, LLC, Exton, Pennsylvania 19341, USA. cschuber@prdus.jnj.com




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Macrophage colony-stimulating factor 1 receptor
A
333Homo sapiensMutation(s): 0 
Gene Names: CSF1R (FMS)
Find proteins for P07333 (Homo sapiens)
Go to Gene View: CSF1R
Go to UniProtKB:  P07333
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
5CN
Query on 5CN

Download SDF File 
Download CCD File 
A
5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE
C19 H21 N3 O3
NNPCFFIJVKYGHR-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
5CNIC50: 24 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.8 Å
  • R-Value Free: 0.282 
  • R-Value Work: 0.237 
  • Space Group: H 3
Unit Cell:
Length (Å)Angle (°)
a = 80.440α = 90.00
b = 80.440β = 90.00
c = 143.760γ = 120.00
Software Package:
Software NamePurpose
CNXrefinement
LSCALEdata scaling
CNXphasing
PROTEUM PLUSdata collection
SAINTdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2006-11-28
    Type: Initial release
  • Version 1.1: 2008-05-01
    Type: Version format compliance
  • Version 1.2: 2011-07-13
    Type: Version format compliance
  • Version 1.3: 2017-08-23
    Type: Refinement description, Source and taxonomy
  • Version 1.4: 2017-10-18
    Type: Refinement description